Influenza remains a global health risk and challenge. Currently, neuraminidase (NA)
inhibitors are extensively used to treat influenza, but their efficacy is compromised by the …

Background Human antibodies that interfere with the biological activity of haemagglutinins
(HAs) of influenza viruses have high potential as an antiviral agent. Methods Human single …

Influenza A virus continuously infects humans and the antigenic shifts of this respiratory virus
enable it to cross the species barrier, threatening public health with the risk of pandemics …

The sporadic outbreaks of highly pathogenic H5N1 avian influenza virus have raised public
health concerns. Monoclonal antibodies (MAbs) against hemagglutinin (HA) have been …

Seasonal influenza viruses are highly contagious, leading to 290,000–650,000 mortalities
every year globally. Among the influenza viruses, influenza A virus (H3N2) has attracted …

Influenza A virus infection is a persistent threat to public health worldwide due to its ability to
evade immune surveillance through rapid genetic drift and shift. Current vaccines against …

Highly pathogenic avian influenza virus subtype H5N1 continues to be a severe threat to
public health, as well as the poultry industry, because of its high lethality and antigenic drift …

Hemagglutinin (HA), the major antigen on the surface of influenza viruses, is the primary
target for neutralizing antibodies and vaccine design. However, frequent mutations in this …

Background Highly pathogenic avian H5 influenza viruses have spread and diversified
genetically and antigenically into multiple clades and subclades. Most isolates of currently …

The DiversitabTM system produces target specific high titer fully human polyclonal IgG
immunoglobulins from transchromosomic (Tc) bovines shown to be safe and effective …